Abstract：
Urticarial vasculitis (UV) is a small vessel leucocytoclastic vasculitis, which often needs to be distinguished from urticaria and other dermatoses. Treatment of UV in children is challenging because of the unsatisfying efficacy of antihistamines and the safety concern of long-term systemic corticosteroids or immunosuppressive agents. As a classic biological agent widely used in chronic spontaneous urticaria, omalizumab might also be a potential therapeutic option in the treatment of children with UV. This report presented four children, aged 4-6 years, with glucocorticoid-unresponsive UV successfully treated by omalizumab, thus providing evidence that omalizumab can be used to treat UV with good efficacy and tolerability in the paediatric population.
摘要：
荨麻疹性血管炎（UV）是一种小血管白细胞碎裂性血管炎，这通常需要与荨麻疹和其他皮肤病区分开来。由于抗组胺药的疗效不佳以及长期全身性皮质类固醇或免疫抑制剂的安全性问题，儿童紫外线的治疗具有挑战性。作为一种广泛应用于慢性自发性荨麻疹的经典生物制剂，奥马珠单抗也可能是治疗紫外线儿童的潜在治疗选择。这份报告介绍了四个孩子，4-6岁，奥马珠单抗成功治疗了糖皮质激素无反应的紫外线，这为奥马珠单抗治疗紫外线提供了证据，在儿科人群中具有良好的疗效和耐受性。
